Kaya Vildan, Yildirim Mustafa, Yazici Gozde, Gunduz Seyda, Bozcuk Hakan, Paydas Semra
Medstar Antalya Hospital, Department of Radiation Oncology, Antalya Education and Research Hospital, Antalya,Turkey. Email:
Asian Pac J Cancer Prev. 2018 May 26;19(5):1169-1173. doi: 10.22034/APJCP.2018.19.5.1169.
Background: Triple-negative breast cancer (TNBC) is a sub-group of breast cancers with a particularly poor prognosis. The results of studies investigating the role of platinum-based chemotherapy (PBC) in metastatic TNBC (mTNBC) have been conflicting. In this meta-analysis, our aim was to assess the effectiveness of PBCs for mTNBCs. Methods: The PubMed, Cochrane Controlled Trials Register Databases, and EBSCOhost databases were accessed. The English language was used as the search language and only human studies were included. The Newcastle–Ottawa Quality Assessment Scale and the Jadad scoring system were used to evaluate the quality of the included randomized controlled studies. Results: Seven studies and 1,571 patients were included in this meta-analysis. The pooled hazard ratio (HR) for overall survival (OS), evaluated on the basis of six studies, showed the use of PBC regimes to be related to OS in mTNBCs (HR 0.620; 95% CI 0.513-0.749; p:<0.001). Four studies containing HR and abstract statistics used for HR calculation were included in the meta-analysis for progression-free survival (PFS). The pooled HR again indicated a significant relation (HR, 0.628; 95% CI, 0.501-0.786; p:<0.001). Conclusions: In this meta-analysis, we confirmed that PBC regimes provide OS and PFS advantages compared to non-PBC regimes. The use of PBC regimes could be a good choice in mTNBC patients for better quality of life and survival.
三阴性乳腺癌（TNBC）是乳腺癌的一个亚组，预后特别差。关于铂类化疗（PBC）在转移性三阴性乳腺癌（mTNBC）中作用的研究结果一直存在争议。在这项荟萃分析中，我们的目的是评估PBC对mTNBC的有效性。方法：检索了PubMed、Cochrane对照试验注册数据库和EBSCOhost数据库。以英语作为检索语言，仅纳入人体研究。采用纽卡斯尔-渥太华质量评估量表和Jadad评分系统评估纳入的随机对照研究的质量。结果：本荟萃分析纳入了7项研究和1571例患者。基于6项研究评估的总生存（OS）合并风险比（HR）显示，PBC方案的使用与mTNBC的OS相关（HR 0.620；95%CI 0.513 - 0.749；p < 0.001）。无进展生存（PFS）的荟萃分析纳入了4项包含HR及用于HR计算的摘要统计数据的研究。合并HR再次表明存在显著相关性（HR，0.628；95%CI，0.501 - 0.786；p < 0.001）。结论：在这项荟萃分析中，我们证实与非PBC方案相比，PBC方案具有OS和PFS优势。对于mTNBC患者，使用PBC方案可能是提高生活质量和生存率的一个不错选择。
